INFINITY Angioplasty Balloon Catheter: Completes 1st In Human Precision Angioplasty

Lucida Medical (Cambridge University Spin-out) Joins GE Healthcare Edison™ Accelerator Programme

Lucida Medical was invited to join the Edison Accelerator programme for its pioneering work in helping identify prostate cancer and its exceptional development team led by Prof Evis Sala and Dr Antony Rix, both highly experienced in artificial intelligence, or AI, medical technology.

Boston Scientific Exercises Option to Acquire Farapulse, Inc.

FARAPULSE Pulsed Field Ablation (PFA) System is a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias.  

Insulet to Present New Clinical Data for Preschool Children and Adults using the Omnipod® 5 System

Insulet will present new clinical outcomes data for preschool children with type 1 diabetes using the Omnipod 5 Automated Insulin Delivery System (Omnipod 5).

November 17, 2020

INFINITY Angioplasty Balloon announced today that its innovative PRECISION ANGIOPLASTY™ balloon platform – INFINITY ANGIOPLASTY BALLOON CATHETER™ has successfully completed a First-in-Human clinical trial. Recently cleared by the FDA for PTA treatment of peripheral artery disease including:

  • iliac
  • femoral
  • popliteal
  • infra-popliteal arteries
  • for the treatment of AV dialysis access

“The INFINITY catheter represents a game-changing innovation in percutaneous angioplasty balloon design and utility,” states founder and vascular surgeon, John Pigott, MD.

John A. Phillips, MD, FSCAI, an interventional cardiologist at OhioHealth Riverside Methodist, performed the first-in-human INFINITY procedure.”I am extremely pleased with the catheter delivery and to-the-mm sizing of the balloon length to the lesion, particularly in this very challenging case,” commented Dr. Phillips.  “The patient was a 60-year-old woman with highly angulated aortic bifurcation and a 78mm CTO in the distal SFA.”

The INFINITY platform is the first and only therapy to provide Precision Angioplasty™, to-the-mm sizing of balloon length to the lesion. Adopting the platform significantly reduces inventory needs and costs from dozens of SKU’s and it reduces shelf space requirements, inventory management time, and trunk stock; while delivering the assurance that the right balloon size will always be on the shelf.

“INFINITY is a highly differentiated product,”  reports CEO Gary Smith.  “This is an ideal product for both Office-Based Labs and Hospitals.”  While initially launching the INFINITY ANGIOPLASTY BALLOON CATHETER, the Company intends to follow quickly with the INFINITY DEFENDER™, a DCB platform of similar design that will assure precise delivery of a drug to the lesion site and minimize downstream and systematic effects.

Key investors: JobsOhio, ProMedica Innovations, Northwest Ohio Tech Fund II, and the Global Cardiovascular Innovation Center. Received 510(K). View here.

 

spot_img

DON'T MISS

Trinity Health Names Mark LePage, M.D., as Senior Vice President of Medical Groups and Ambulatory Strategy

Prior to his time at IHA, LePage served as chief medical officer of Marshfield Clinic in Wisconsin

Jody Crane, MD Recognized by Modern Healthcare As One of the 50 Most Influential Clinical Executives

Dr. Crane’s work to streamline operations positioned and prepared TeamHealth and its clinicians to face the COVID-19 pandemic. Under Dr. Crane’s leadership, TeamHealth was able to maintain high levels of clinical quality throughout the rapidly changing COVID environment.

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

Subscribe to Medical Device News Magazine here.

Related Articles